
Claudio Tiribelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/764133/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 2020, 73, 202-209.	1.8	2,171
2	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	0.6	1,840
3	The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterology, 2006, 6, 33.	0.8	1,817
4	Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology, 2005, 42, 44-52.	3.6	1,118
5	Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy. Annals of Internal Medicine, 2000, 132, 112.	2.0	1,051
6	Prevalence of chronic liver disease in the general population of northern Italy: The dionysos study. Hepatology, 1994, 20, 1442-1449.	3.6	504
7	Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology, 2016, 63, 827-838.	3.6	467
8	The Many Functions of APE1/Ref-1: Not Only a DNA Repair Enzyme. Antioxidants and Redox Signaling, 2009, 11, 601-619.	2.5	424
9	Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology, 2004, 126, 102-110.	0.6	389
10	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	9.4	389
11	Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends in Molecular Medicine, 2008, 14, 72-81.	3.5	381
12	Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. Journal of Magnetic Resonance Imaging, 1995, 5, 281-285.	1.9	340
13	Global epidemiology of nonâ€alcoholic fatty liver disease/nonâ€alcoholic steatohepatitis: What we need in the future. Liver International, 2018, 38, 47-51.	1.9	297
14	Bilirubin-Induced Neurologic Damage — Mechanisms and Management Approaches. New England Journal of Medicine, 2013, 369, 2021-2030.	13.9	284
15	Noninvasive in vivo quantitative assessment of fat content in human liver. Journal of Hepatology, 1997, 27, 108-113.	1.8	283
16	Fatty Infiltration of the Liver. Investigative Radiology, 1993, 28, 297-302.	3.5	222
17	The spectrum of liver disease in the general population: lesson from the Dionysos study. Journal of Hepatology, 2001, 35, 531-537.	1.8	213
18	Severity of liver disease with different hepatitis C viral clones. Lancet, The, 1991, 338, 509.	6.3	199

#	Article	IF	CITATIONS
19	Incidence and natural course of fatty liver in the general population: The Dionysos study. Hepatology, 2007, 46, 1387-1391.	3.6	192
20	A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterology, 2010, 10, 98.	0.8	188
21	Hepatitis C virus and nonâ€Hodgkin's lymphomas. British Journal of Haematology, 1996, 94, 544-550.	1.2	171
22	Molecular basis of bilirubin-induced neurotoxicity. Trends in Molecular Medicine, 2004, 10, 65-70.	3.5	171
23	Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. Journal of Medical Virology, 1994, 43, 291-296.	2.5	156
24	Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus–related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology, 2007, 46, 1009-1015.	3.6	150
25	Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1). Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2470-2475.	3.3	148
26	A Novel Perspective on the Biology of Bilirubin in Health and Disease. Trends in Molecular Medicine, 2016, 22, 758-768.	3.5	147
27	High prevalence of celiac disease in Italian general population. Digestive Diseases and Sciences, 2001, 46, 1500-1505.	1.1	138
28	Differential expression of the multidrug resistanceâ€related proteins ABCb1 and ABCc1 between bloodâ€brain interfaces. Journal of Comparative Neurology, 2008, 510, 497-507.	0.9	135
29	The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Medicine, 2009, 7, 21.	2.3	132
30	Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. Clinical Science, 2015, 129, 1-25.	1.8	126
31	Unbound (Free) Bilirubin: Improving the Paradigm for Evaluating Neonatal Jaundice. Clinical Chemistry, 2009, 55, 1288-1299.	1.5	124
32	Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells. Gastroenterology, 1998, 115, 157-166.	0.6	120
33	The epidemiology of fatty liver. European Journal of Gastroenterology and Hepatology, 2004, 16, 1087-1093.	0.8	116
34	Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterology, 2012, 12, 20.	0.8	109
35	Neonatal Jaundice in Low- and Middle-Income Countries: Lessons and Future Directions from the 2015 Don Ostrow Trieste Yellow Retreat. Neonatology, 2016, 110, 172-180.	0.9	108
36	Bilirubin mediated oxidative stress involves antioxidant response activation via Nrf2 pathway. Cellular Signalling, 2014, 26, 512-520.	1.7	106

#	Article	lF	CITATIONS
37	Affinity of Human Serum Albumin for Bilirubin Varies with Albumin Concentration and Buffer Composition. Journal of Biological Chemistry, 2001, 276, 29953-29960.	1.6	101
38	DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. Journal of Hepatology, 2001, 34, 587-592.	1.8	96
39	Molecular Mechanisms for the Hepatic Uptake of Magnetic Resonance Imaging Contrast Agents. Biochemical and Biophysical Research Communications, 1999, 257, 746-752.	1.0	95
40	Subcellular Localization of APE1/Ref-1 in Human Hepatocellular Carcinoma: Possible Prognostic Significance. Molecular Medicine, 2007, 13, 89-96.	1.9	93
41	Familial clustering of Helicobacter pylori infection: population based study Commentary: Helicobacter pylorithe story so far. BMJ: British Medical Journal, 1999, 319, 537-541.	2.4	92
42	Inhibition of Glutamate Uptake by Unconjugated Bilirubin in Cultured Cortical Rat Astrocytes: Role of Concentration and pH. Biochemical and Biophysical Research Communications, 1999, 265, 67-72.	1.0	92
43	Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity. Cancers, 2020, 12, 1576.	1.7	90
44	Effects of maturation on RNA transcription and protein expression of four MRP genes in human placenta and in BeWo cells. Biochemical and Biophysical Research Communications, 2003, 303, 259-265.	1.0	87
45	Reassessment of the Unbound Concentrations of Unconjugated Bilirubin in Relation to Neurotoxicity In Vitro. Pediatric Research, 2003, 54, 98-104.	1.1	85
46	Prevalence of hepatocellular carcinoma and relation to cirrhosis: Comparison of two different cities of the world—Trieste, Italy, and Chiba, Japan. Hepatology, 1989, 10, 998-1002.	3.6	80
47	Isolation of a sulfobromophthalein-binding protein from hepatocyte plasma membrane. Biochimica Et Biophysica Acta (BBA) - Protein Structure, 1978, 532, 105-112.	1.7	78
48	Effect of tauroursodeoxycholic and ursodeoxycholic acid on ethanol-induced cell injuries in the human Hep G2 cell line. Gastroenterology, 1995, 109, 555-563.	0.6	78
49	Bilirubin inhibits the TNFα-related induction of three endothelial adhesion molecules. Biochemical and Biophysical Research Communications, 2009, 386, 338-344.	1.0	76
50	Genetic Determinants of Ethanol-Induced Liver Damage. Molecular Medicine, 2001, 7, 255-262.	1.9	75
51	Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor–induced cell death by replenishing mitochondrial glutathione. Hepatology, 2001, 34, 964-971.	3.6	75
52	Natural Course of Chronic HCV and HBV Infection and Role of Alcohol in the General Population: The Dionysos Study. American Journal of Gastroenterology, 2008, 103, 2248-2253.	0.2	75
53	Kinetics and Specificity of Feline Leukemia Virus Subgroup C Receptor (FLVCR) Export Function and Its Dependence on Hemopexin. Journal of Biological Chemistry, 2010, 285, 28874-28882.	1.6	74
54	Life-Long Correction of Hyperbilirubinemia with a Neonatal Liver-Specific AAV-Mediated Gene Transfer in a Lethal Mouse Model of Crigler–Najjar Syndrome. Human Gene Therapy, 2014, 25, 844-855.	1.4	74

#	Article	IF	CITATIONS
55	Rescue of bilirubinâ€induced neonatal lethality in a mouse model of Criglerâ€Najjar syndrome type I by AAV9â€mediated gene transfer. FASEB Journal, 2012, 26, 1052-1063.	0.2	71
56	Epidemiology of fatty liver: an update. World Journal of Gastroenterology, 2014, 20, 9050-4.	1.4	71
57	The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In Vivo and In Vitro Study. PLoS ONE, 2013, 8, e76830.	1.1	70
58	Galectin-1 and Its Involvement in Hepatocellular Carcinoma Aggressiveness. Molecular Medicine, 2010, 16, 102-115.	1.9	69
59	The products of YCF1 and YLL015w (BPT1) cooperate for the ATP-dependent vacuolar transport of unconjugated bilirubin in Saccharomyces cerevisiae. Yeast, 2000, 16, 561-571.	0.8	68
60	Factors Affecting the Binding of Bilirubin to Serum Albumins: Validation and Application of the Peroxidase Method. Pediatric Research, 2006, 60, 724-728.	1.1	67
61	Biochemical and molecular aspects of the hepatic uptake of organic anions. BBA - Biomembranes, 1990, 1031, 261-275.	7.9	65
62	The human multidrug-resistance-associated protein MRP1 mediates ATP-dependent transport of unconjugated bilirubin. Biochemical Journal, 2004, 383, 335-341.	1.7	65
63	ABC Protein Transport of MRI Contrast Agents in Canalicular Rat Liver Plasma Vesicles and Yeast Vacuoles. Biochemical and Biophysical Research Communications, 2001, 282, 60-66.	1.0	63
64	Reconstitution in vitro of sulfobromophthalein transport by bilitranslocase. Biochimica Et Biophysica Acta - Biomembranes, 1982, 685, 123-128.	1.4	62
65	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	1.8	62
66	Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. Journal of Medical Virology, 2002, 68, 352-356.	2.5	60
67	Bilirubin and the risk of common non-hepatic diseases. Trends in Molecular Medicine, 2005, 11, 277-283.	3.5	60
68	Cytotoxicity Is Predicted by Unbound and Not Total Bilirubin Concentration. Pediatric Research, 2007, 62, 576-580.	1.1	60
69	Mechanisms for the transport of unconjugated bilirubin in human trophoblastic BeWo cells. FEBS Letters, 2001, 495, 94-99.	1.3	58
70	Overoxidation of peroxiredoxins as an immediate and sensitive marker of oxidative stress in HepG2 cells and its application to the redox effects induced by ischemia/reperfusion in human liver. Free Radical Research, 2005, 39, 255-268.	1.5	58
71	Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. Journal of Hepatology, 1993, 19, 459-464.	1.8	57
72	The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis. BMC Cancer, 2015, 15, 188.	1.1	55

#	Article	IF	CITATIONS
73	Further studies on bilitranslocase, a plasma membrane protein involved in hepatic organic anion uptake. Biochimica Et Biophysica Acta - Biomembranes, 1982, 685, 117-122.	1.4	54
74	Proteomic analysis of liver tissues subjected to early ischemia/reperfusion injury during human orthotopic liver transplantation. Proteomics, 2006, 6, 3455-3465.	1.3	53
75	Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity?. Clinical Pharmacology and Therapeutics, 2019, 106, 568-575.	2.3	53
76	Molecular Determinants in the Transport of a Bile Acid-Derived Diagnostic Agent in Tumoral and Nontumoral Cell Lines of Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 809-817.	1.3	51
77	Alterations in the redox state and liver damage: Hints from the EASL Basic School of Hepatology. Journal of Hepatology, 2013, 58, 365-374.	1.8	51
78	Serum type III procollagen peptide in alcoholic liver disease and idiopathic hemochromatosis: Its relationship to hepatic fibrosis, activity of the disease and iron overload. Hepatology, 1985, 5, 475-479.	3.6	49
79	Ethanol-induced apoptosis in vitro. Clinical Biochemistry, 1999, 32, 547-555.	0.8	49
80	Gene Expression of ABC Proteins in Hepatocellular Carcinoma, Perineoplastic Tissue, and Liver Diseases. Molecular Medicine, 2002, 8, 318-325.	1.9	49
81	The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH. Toxicology in Vitro, 2015, 29, 1753-1758.	1.1	49
82	Modulation of Mrp1 (ABCc1) and Pgp (ABCb1) by Bilirubin at the Blood-CSF and Blood-Brain Barriers in the Gunn Rat. PLoS ONE, 2011, 6, e16165.	1.1	48
83	Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients. Journal of Hepatology, 2017, 67, 1018-1025.	1.8	48
84	Vitamin D, Homocysteine, and Folate in Subcortical Vascular Dementia and Alzheimer Dementia. Frontiers in Aging Neuroscience, 2017, 9, 169.	1.7	48
85	Bilirubin: The yellow hormone?. Journal of Hepatology, 2021, 75, 1485-1490.	1.8	47
86	Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World Journal of Gastroenterology, 2016, 22, 1497.	1.4	47
87	Cellular localization of sulfobromophthalein transport activity in rat liver. Biochimica Et Biophysica Acta - Biomembranes, 1986, 856, 1-10.	1.4	46
88	Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. Journal of Hepatology, 1998, 29, 650-659.	1.8	45
89	Bilirubin accumulation and Cyp mRNA expression in selected brain regions of jaundiced Gunn rat pups. Pediatric Research, 2012, 71, 653-660.	1.1	45
90	An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. PLoS ONE, 2016, 11, e0158817.	1.1	45

#	Article	lF	CITATIONS
91	Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterology, 2012, 12, 160.	0.8	44
92	Interferon therapy in chronic hepatitis C virus: Evidence of different outcome with respect to different viral strains. Journal of Medical Virology, 1995, 45, 445-450.	2.5	43
93	Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World Journal of Gastroenterology, 2014, 20, 9038-49.	1.4	43
94	The importance of the interaction between hepatocyte and hepatic stellate cells in fibrogenesis induced by fatty accumulation. Experimental and Molecular Pathology, 2015, 98, 85-92.	0.9	42
95	Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World Journal of Hepatology, 2010, 2, 114.	0.8	42
96	Blood Flow Changes in Hepatocellular Carcinoma After the Administration of Thalidomide Assessed by Reperfusion Kinetics During Microbubble Infusion. Investigative Radiology, 2006, 41, 15-21.	3.5	41
97	Bilirubin-induced cell toxicity involves PTEN activation through an APE1/Ref-1-dependent pathway. Journal of Molecular Medicine, 2007, 85, 1099-1112.	1.7	41
98	Bilirubin-Induced Oxidative Stress Leads to DNA Damage in the Cerebellum of Hyperbilirubinemic Neonatal Mice and Activates DNA Double-Strand Break Repair Pathways in Human Cells. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-11.	1.9	41
99	The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and Their Clinical Implications. Cancers, 2020, 12, 823.	1.7	40
100	Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World Journal of Gastroenterology, 2016, 22, 9096.	1.4	39
101	Attenuation of neuro-inflammation improves survival and neurodegeneration in a mouse model of severe neonatal hyperbilirubinemia. Brain, Behavior, and Immunity, 2018, 70, 166-178.	2.0	39
102	Magnetic Resonance Contrast Agents: From the Bench to the Patient. Current Pharmaceutical Design, 2005, 11, 4079-4098.	0.9	38
103	The role of microRNA in the resistance to treatment of hepatocellular carcinoma. Annals of Translational Medicine, 2019, 7, 577-577.	0.7	38
104	In vitro and in vivo hepatic transport of the magnetic resonance imaging contrast agent B22956/1: role of MRP proteins. Biochemical and Biophysical Research Communications, 2002, 293, 100-105.	1.0	37
105	Specific Inhibition of the Redox Activity of Ape1/Ref-1 by E3330 Blocks Tnf-Î [*] -Induced Activation of II-8 Production in Liver Cancer Cell Lines. PLoS ONE, 2013, 8, e70909.	1.1	37
106	Hepatic uptake of organic anions affects the plasma bilirubin level in subjects with Gilbert's syndrome mutations in UGT1A1. Hepatology, 2001, 33, 627-632.	3.6	36
107	Mechanisms of bilirubin neurotoxicity. Hepatology, 2002, 35, 1277-1280.	3.6	36
108	Epidemiology of hepatitis C virus infection in Italy: the slowly unraveling mystery. Microbes and Infection, 2000, 2, 1757-1763.	1.0	34

#	Article	IF	CITATIONS
109	Liver and heart: A new link?. Journal of Hepatology, 2008, 49, 300-302.	1.8	33
110	New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. Journal of Controlled Release, 2017, 268, 184-197.	4.8	33
111	Serum AP-endonuclease 1 (sAPE1) as novel biomarker for hepatocellular carcinoma. Oncotarget, 2019, 10, 383-394.	0.8	33
112	A proteomic approach to the bilirubinâ€induced toxicity in neuronal cells reveals a protective function of DJâ€1 protein. Proteomics, 2010, 10, 1645-1657.	1.3	32
113	Is it time to change NAFLD and NASH nomenclature?. The Lancet Gastroenterology and Hepatology, 2017, 2, 547-548.	3.7	32
114	Gene Expression Analysis in HBV Transgenic Mouse Liver: A Model to Study Early Events Related to Hepatocarcinogenesis. Molecular Medicine, 2006, 12, 115-123.	1.9	31
115	Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals. Cancers, 2019, 11, 1773.	1.7	31
116	A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients. Scientific Reports, 2019, 9, 8265.	1.6	31
117	Spleen Stiffness Probability Index (SSPI): A simple and accurate method to detect esophageal varices in patients with compensated liver cirrhosis. Annals of Hepatology, 2020, 19, 53-61.	0.6	31
118	Bilirubin, Intestinal Integrity, the Microbiome, and Inflammation. New England Journal of Medicine, 2020, 383, 684-686.	13.9	31
119	Transport of sulfobromophthalein and taurocholate in the HepG2 cell line in relation to the expression of membrane carrier proteins. Biochemical and Biophysical Research Communications, 1992, 183, 1203-1208.	1.0	30
120	Effective Treatment of Unconjugated Hyperbilirubinemia With Oral Bile Salts in Gunn Rats. Gastroenterology, 2009, 136, 673-682.e1.	0.6	30
121	Transcriptional Up-Regulation of APE1/Ref-1 in Hepatic Tumor: Role in Hepatocytes Resistance to Oxidative Stress and Apoptosis. PLoS ONE, 2015, 10, e0143289.	1.1	30
122	Bilirubin effect on endothelial adhesion molecules expression is mediated by the NF-kappaB signaling pathway. BioScience Trends, 2009, 3, 151-7.	1.1	30
123	Albumin binding of unconjugated [3H]bilirubin and its uptake by rat liver basolateral plasma membrane vesicles. Biochemical Journal, 1996, 316, 999-1004.	1.7	29
124	Multidrug resistance associated protein 1 protects against bilirubin-induced cytotoxicity. FEBS Letters, 2006, 580, 1355-1359.	1.3	29
125	Transport and Metabolism at Blood–Brain Interfaces and in Neural Cells: Relevance to Bilirubin-Induced Encephalopathy. Frontiers in Pharmacology, 2012, 3, 89.	1.6	29
126	Bilirubin-induced ER stress contributes to the inflammatory response and apoptosis in neuronal cells. Archives of Toxicology, 2017, 91, 1847-1858.	1.9	29

#	Article	IF	CITATIONS
127	Intestinal flora and bilirubin. Journal of Hepatology, 2005, 42, 170-172.	1.8	28
128	Functional Induction of the Cystine-Glutamate Exchanger System Xc- Activity in SH-SY5Y Cells by Unconjugated Bilirubin. PLoS ONE, 2011, 6, e29078.	1.1	28
129	Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis. Nutrients, 2017, 9, 1006.	1.7	28
130	Hepatitis B virus genotypes, core promoter variants, and precore stop codon variants in patients infected chronically in North-Eastern Italy. Journal of Medical Virology, 2006, 78, 734-740.	2.5	27
131	Circulating Long and Circular Noncoding RNA as Non-Invasive Diagnostic Tools of Hepatocellular Carcinoma. Biomedicines, 2021, 9, 90.	1.4	27
132	Homocysteine in Neurology: A Possible Contributing Factor to Small Vessel Disease. International Journal of Molecular Sciences, 2021, 22, 2051.	1.8	27
133	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 2021, 160, 2483-2495.e26.	0.6	27
134	The Biological Effects of Bilirubin Photoisomers. PLoS ONE, 2016, 11, e0148126.	1.1	27
135	Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat. Digestive Diseases and Sciences, 1993, 38, 1291-1296.	1.1	26
136	Rapid Method for Detection of Extra (TA) in the Promoter of the Bilirubin-UDP-Glucuronosyl Transferase 1 Gene Associated with Gilbert Syndrome. Clinical Chemistry, 2000, 46, 129-131.	1.5	26
137	A transcriptome analysis identifies molecular effectors of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells. BMC Genomics, 2009, 10, 543.	1.2	26
138	Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. Scientific Reports, 2020, 10, 1699.	1.6	26
139	Genetic biomarkers for hepatocellular cancer risk in a caucasian population. World Journal of Gastroenterology, 2017, 23, 6674-6684.	1.4	26
140	Modeling, identification and parameter estimation of bilirubin kinetics in normal, hemolytic and Gilbert's states. Journal of Biomedical Informatics, 1975, 8, 522-537.	0.7	25
141	Low solubility of unconjugated bilirubin in dimethylsulfoxidewater systems: implications for pKa determinations. BMC Biochemistry, 2002, 3, 17.	4.4	25
142	The molecular basis of jaundice: An old symptom revisited. Liver International, 2017, 37, 1094-1102.	1.9	25
143	Hyaluronic acid inhibition by 4-methylumbelliferone reduces the expression of cancer stem cells markers during hepatocarcinogenesis. Scientific Reports, 2019, 9, 4026.	1.6	25
144	Differentiation between stages of non-alcoholic fatty liver diseases using surface-enhanced Raman spectroscopy. Analytica Chimica Acta, 2020, 1110, 190-198.	2.6	25

#	Article	IF	CITATIONS
145	The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer. Cancers, 2021, 13, 1168.	1.7	25
146	Sex differences of nicotinate-induced hyperbilirubinemia in Gilbert's syndrome. Journal of Hepatology, 1985, 1, 417-429.	1.8	24
147	Reversal of ethinylestradiol-induced cholestasis by epomediol in rat. Biochemical Pharmacology, 1989, 38, 3559-3563.	2.0	24
148	Clinical, biochemical and histological features of primary haemochromatosis: a report of 67 cases. Liver, 1986, 6, 310-315.	0.1	24
149	Epomediol ameliorates pruritus in patients with intrahepatic cholestasis of pregnancy. Journal of Hepatology, 1992, 16, 241-242.	1.8	23
150	Evaluation of region selective bilirubin-induced brain damage as a basis for a pharmacological treatment. Scientific Reports, 2017, 7, 41032.	1.6	23
151	The activation of autophagy protects neurons and astrocytes against bilirubin-induced cytotoxicity. Neuroscience Letters, 2017, 661, 96-103.	1.0	23
152	Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. BMC Gastroenterology, 2018, 18, 177.	0.8	23
153	Serum Marker of Type III Procollagen in Patients with Idiopathic Hemochromatosis and Its Relationship to Hepatic Fibrosis. American Journal of Clinical Pathology, 1983, 80, 499-502.	0.4	22
154	Measurement of the association of cholephylic organic anions with different binding proteins. Biochemical Pharmacology, 1985, 34, 2439-2444.	2.0	22
155	Mechanisms of hepatic uptake of organic anions. Clinical Science, 1986, 71, 1-8.	1.8	22
156	[6] Isolation of bilitranslocase, the anion transporter from liver plasma membrane for bilirubin and other organic anions. Methods in Enzymology, 1989, 174, 50-57.	0.4	22
157	Correspondence. Pediatric Research, 2003, 54, 926-926.	1.1	22
158	SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1217-25.	1.4	22
159	The cytotoxic effect of unconjugated bilirubin in human neuroblastoma SH-SY5Y cells is modulated by the expression level of MRP1 but not MDR1. Biochemical Journal, 2009, 417, 305-312.	1.7	22
160	Diagnostic methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments. Pediatric Research, 2021, 90, 277-283.	1.1	22
161	Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates. International Journal of Molecular Sciences, 2022, 23, 2764.	1.8	22
162	Uptake of [3H]bilirubin in freshly isolated rat hepatocytes: role of free bilirubin concentration. FEBS Letters, 1999, 463, 143-145.	1.3	21

#	Article	IF	CITATIONS
163	New concepts in bilirubin neurotoxicity and the need for studies at clinically relevant bilirubin concentrations. Journal of Hepatology, 2001, 34, 467-470.	1.8	21
164	Preparation of an Antibody Recognizing both Human and Rodent MRP1. Biochemical and Biophysical Research Communications, 2001, 288, 1064-1068.	1.0	21
165	Circulatory miRNA as a Biomarker for Therapy Response and Disease-Free Survival in Hepatocellular Carcinoma. Cancers, 2020, 12, 2810.	1.7	21
166	The implication of bilitranslocase function in the impaired rifamycin SV metabolism in Gilbert's syndrome. Clinical Science, 1985, 68, 675-680.	1.8	20
167	Abnormal hepatic uptake of low doses of sulfobromophthalein in Gilbert's syndrome: The role of reduced affinity of the plasma membrane carrier of organic anions. Hepatology, 1990, 12, 213-217.	3.6	20
168	Determinants in the hepatic uptake of organic anions. Journal of Hepatology, 1992, 14, 385-390.	1.8	20
169	Upregulation in the expression of multidrug resistance protein Mrp1 mRNA and protein by increased bilirubin production in rat. Biochemical and Biophysical Research Communications, 2003, 311, 891-896.	1.0	20
170	Diagnostic Performance Analysis of the Point-of-Care Bilistick System in Identifying Severe Neonatal Hyperbilirubinemia by a Multi-Country Approach. EClinicalMedicine, 2018, 1, 14-20.	3.2	20
171	Comparison of nicotinic acid- and caloric restriction-induced hyperbilirubinaemia in the diagnosis of gilbert's syndrome. Journal of Hepatology, 1985, 1, 537-543.	1.8	19
172	Chronic Administration of Ursodeoxycholic and Tauroursodeoxycholic Acid Changes Microsomal Membrane Lipid Content and Fatty Acid Composition in Rats. Biochemical and Biophysical Research Communications, 1996, 220, 479-483.	1.0	19
173	Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 403-408.	1.7	19
174	Systematic review and meta-analysis on the adverse events of rimonabant treatment: Considerations for its potential use in hepatology. BMC Gastroenterology, 2009, 9, 75.	0.8	19
175	Alterations in the Cell Cycle in the Cerebellum of Hyperbilirubinemic Gunn Rat: A Possible Link with Apoptosis?. PLoS ONE, 2013, 8, e79073.	1.1	19
176	The Extent of Intracellular Accumulation of Bilirubin Determines Its Anti- or Pro-Oxidant Effect. International Journal of Molecular Sciences, 2020, 21, 8101.	1.8	19
177	Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population?. Annals of Hepatology, 2020, 19, 380-387.	0.6	19
178	Sex steroid modulation of the hepatic uptake of organic anions in rat. Journal of Hepatology, 1988, 6, 343-349.	1.8	18
179	Novel Kinetic Insights into Treatment of Unconjugated Hyperbilirubinemia: Phototherapy and Orlistat Treatment in Gunn Rats. Pediatric Research, 2006, 59, 506-512.	1.1	18
180	Effect of bilirubin on cytochrome c oxidase activity of mitochondria from mouse brain and liver. BMC Research Notes, 2010, 3, 162.	0.6	18

#	Article	IF	CITATIONS
181	UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population. Liver International, 2017, 37, 1345-1353.	1.9	18
182	Bilirubin disrupts calcium homeostasis in neonatal hippocampal neurons: a new pathway of neurotoxicity. Archives of Toxicology, 2020, 94, 845-855.	1.9	18
183	Screening methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments. Pediatric Research, 2021, 90, 272-276.	1.1	18
184	Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease. , 2020, 1, 51-74.		18
185	Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research. World Journal of Hepatology, 2018, 10, 231-245.	0.8	18
186	Effect of ethinylestradiol and epomediol on bile flow and biliary lipid composition in rat. Biochemical Pharmacology, 1992, 43, 1289-1293.	2.0	17
187	ATP-dependent transport of unconjugated bilirubin by rat liver canalicular plasma membrane vesicles. Biochemical Journal, 1998, 331, 99-103.	1.7	17
188	Abnormal apolipoprotein B pre-mRNA splicing in patients with familial hypobetalipoproteinaemia. Journal of Medical Genetics, 2006, 44, 219-224.	1.5	17
189	Role of brain cytochrome P450 mono-oxygenases in bilirubin oxidation-specific induction and activity. Archives of Toxicology, 2016, 90, 279-290.	1.9	17
190	Histone acetylation as a new mechanism for bilirubin-induced encephalopathy in the Gunn rat. Scientific Reports, 2018, 8, 13690.	1.6	17
191	Weighted miRNA co-expression networks analysis identifies circulating miRNA predicting overall survival in hepatocellular carcinoma patients. Scientific Reports, 2020, 10, 18967.	1.6	17
192	Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes. Annals of Hepatology, 2014, 13, 113-120.	0.6	16
193	The multiple origin of cancer stem cells in hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, S92-S97.	0.7	16
194	Earliest Mechanisms of Dopaminergic Neurons Sufferance in a Novel Slow Progressing Ex Vivo Model of Parkinson Disease in Rat Organotypic Cultures of Substantia Nigra. International Journal of Molecular Sciences, 2019, 20, 2224.	1.8	15
195	The Role of Bilirubin and the Other "Yellow Players―in Neurodegenerative Diseases. Antioxidants, 2020, 9, 900.	2.2	15
196	Optimization of Point-Shear Wave Elastography by Skin-to-Liver Distance to Assess Liver Fibrosis in Patients Undergoing Bariatric Surgery. Diagnostics, 2020, 10, 795.	1.3	15
197	Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study. Journal of Clinical Medicine, 2020, 9, 1177.	1.0	15
198	External Validation of Surrogate Indices of Fatty Liver in the General Population: The Bagnacavallo Study. Journal of Clinical Medicine, 2021, 10, 520.	1.0	15

#	Article	IF	CITATIONS
199	Unconjugated bilirubin modulates nitric oxide production via iNOS regulation. BioScience Trends, 2010, 4, 244-8.	1.1	15
200	Detection of MRP1 mRNA in Human Tumors and Tumor Cell Lines by in Situ RT-PCR. Biochemical and Biophysical Research Communications, 2000, 275, 466-471.	1.0	14
201	Cohort effect of HCV infection in liver cirrhosis assessed by a 25 year study. Journal of Clinical Virology, 2000, 17, 51-56.	1.6	14
202	Differential Proteomic Analysis of Subfractioned Human Hepatocellular Carcinoma Tissues. Journal of Proteome Research, 2009, 8, 2273-2284.	1.8	14
203	Bilirubin-Induced Neurologic Damage. New England Journal of Medicine, 2014, 370, 978-979.	13.9	14
204	A Hypothesis for Using Pathway Genetic Load Analysis for Understanding Complex Outcomes in Bilirubin Encephalopathy. Frontiers in Neuroscience, 2016, 10, 376.	1.4	14
205	Cross-Talk Between Neurons and Astrocytes in Response to Bilirubin: Adverse Secondary Impacts. Neurotoxicity Research, 2014, 26, 1-15.	1.3	13
206	Silencing efficacy prediction: a retrospective study on target mRNA features. Bioscience Reports, 2015, 35, .	1.1	13
207	Modulation of bilirubin neurotoxicity by the Abcb1 transporter in theUgt1-/-lethal mouse model of neonatal hyperbilirubinemia. Human Molecular Genetics, 2016, 26, ddw375.	1.4	13
208	COVID-19 Lockdown Effect on Not Institutionalized Patients with Dementia and Caregivers. Healthcare (Switzerland), 2021, 9, 893.	1.0	13
209	Bilirubin and inflammation in neurodegenerative and other neurological diseases. Neuroimmunology and Neuroinflammation, 0, 2020, .	1.4	13
210	Risk factors for alcoholic liver disease. Addiction Biology, 2000, 5, 261-268.	1.4	12
211	Heterologous Ferredoxin Reductase and Flavodoxin Protect Cos-7 Cells from Oxidative Stress. PLoS ONE, 2010, 5, e13501.	1.1	12
212	Xâ€ray fluorescence elemental mapping and microscopy to follow hepatic disposition of a Gdâ€based magnetic resonance imaging contrast agent. Clinical and Experimental Pharmacology and Physiology, 2011, 38, 834-845.	0.9	12
213	The effect of a hydrogen sulfide releasing molecule (Na2S) on the cold storage of livers from cardiac dead donor rats. A study in an ex vivo model. Cryobiology, 2015, 71, 24-32.	0.3	12
214	HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development. Cancers, 2021, 13, 2485.	1.7	12
215	Pitfalls in preparation of 3H-unconjugated bilirubin by biosynthetic labeling from precursor 3H-5-aminolevulinic acid in the dog. Translational Research, 2001, 138, 313-321.	2.4	11
216	Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. Journal of Endocrinological Investigation, 2014, 37, 739-744.	1.8	11

#	Article	IF	CITATIONS
217	Activation of hepatic stem cells compartment during hepatocarcinogenesis in a HBsAg HBV-transgenic mouse model. Scientific Reports, 2018, 8, 13168.	1.6	11
218	Occult hepatitis B virus infection predicts nonâ€alcoholic steatohepatitis in severely obese individuals from Italy. Liver International, 2020, 40, 1601-1609.	1.9	11
219	Homocysteine in Neurology: From Endothelium to Neurodegeneration. Current Nutrition and Food Science, 2017, 13, .	0.3	11
220	Evaluation of liver parenchymal blood flow with contrast-enhanced US. Academic Radiology, 2003, 10, 869-876.	1.3	10
221	Anti-Transglutaminase Antibodies and Age. Clinical Chemistry, 2004, 50, 1856-1860.	1.5	10
222	Are non-invasive tests accurate enough to predict hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD)?. Gut, 2008, 57, 1351-1353.	6.1	10
223	Modern strategies to identify new molecular targets for the treatment of liver diseases: The promising role of Proteomics and Redox Proteomics investigations. Proteomics - Clinical Applications, 2009, 3, 242-262.	0.8	10
224	Cryopreservation by slow cooling of rat neuronal cells. Cryobiology, 2016, 72, 191-197.	0.3	10
225	Spleen stiffness can be employed to assess the efficacy of spontaneous portosystemic shunts in relieving portal hypertension. Annals of Hepatology, 2020, 19, 691-693.	0.6	10
226	Differences in circulating microRNA signature in Prader–Willi syndrome and non-syndromic obesity. Endocrine Connections, 2018, 7, 1262-1274.	0.8	10
227	Estimation of the hepatic blood "flow―by galactose plasma clearance in patients with liver disease. Liver, 1985, 5, 129-133.	0.1	9
228	Selection and validation of miR-1280 as a suitable endogenous normalizer for qRT-PCR Analysis of serum microRNA expression in Hepatocellular Carcinoma. Scientific Reports, 2020, 10, 3128.	1.6	9
229	Association of Serum Bilirubin Level with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study of 1672 Obese Children. Journal of Clinical Medicine, 2021, 10, 2812.	1.0	9
230	The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular). Current Medicinal Chemistry, 2015, 22, 2954-2971.	1.2	9
231	MicroRNAs Related to TACE Treatment Response: A Review of the Literature from a Radiological Point of View. Diagnostics, 2022, 12, 374.	1.3	9
232	An improved method for isolation of unconjugated bilirubin from rat and dog bile. Translational Research, 2001, 137, 370-373.	2.4	8
233	Bilirubin-induced neurological damage. Journal of Maternal-Fetal and Neonatal Medicine, 2011, 24, 154-155.	0.7	8
234	Silybin Modulates Collagen Turnover in an In Vitro Model of NASH. Molecules, 2019, 24, 1280.	1.7	8

#	Article	IF	CITATIONS
235	Curcumin Prevents Cerebellar Hypoplasia and Restores the Behavior in Hyperbilirubinemic Gunn Rat by a Pleiotropic Effect on the Molecular Effectors of Brain Damage. International Journal of Molecular Sciences, 2021, 22, 299.	1.8	8
236	The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH). International Journal of Molecular Sciences, 2022, 23, 3562.	1.8	8
237	Translational Approach to the Protective Effect of Bilirubin in Diabetic Kidney Disease. Biomedicines, 2022, 10, 696.	1.4	8
238	Vascular network expansion, integrity of blood–brain interfaces, and cerebrospinal fluid cytokine concentration during postnatal development in the normal and jaundiced rat. Fluids and Barriers of the CNS, 2022, 19, .	2.4	8
239	The biological implication of cancer stem cells in hepatocellular carcinoma: a possible target for future therapy. Expert Review of Gastroenterology and Hepatology, 2013, 7, 749-757.	1.4	7
240	Podocyte Expression of Membrane Transporters Involved in Puromycin Aminonucleoside-Mediated Injury. PLoS ONE, 2013, 8, e66159.	1.1	7
241	Bilirubin: A Promising Therapy for Parkinson's Disease. International Journal of Molecular Sciences, 2021, 22, 6223.	1.8	7
242	Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. World Journal of Stem Cells, 2021, 13, 795-824.	1.3	7
243	Taste perception and expression in stomach of bitter taste receptor tas2r38 in obese and lean subjects. Appetite, 2021, 166, 105595.	1.8	7
244	Difference in hepatic uptake of tetra- and Di-bromosulfophthalein in rat. Biochemical Pharmacology, 1993, 46, 925-931.	2.0	6
245	Editorial: The North-to-South Gradient of Hepatitis C Virus Infection. Scandinavian Journal of Gastroenterology, 2003, 38, 805-806.	0.6	6
246	Gene expression and activity of urea cycle enzymes of rat hepatocytes cold stored up to 120h in University of Wisconsin solution. Cryobiology, 2006, 52, 393-400.	0.3	6
247	HCC occurrence after DAA treatments: molecular tools to assess the post-treatment risk and surveillance. Hepatic Oncology, 2020, 7, HEP21.	4.2	6
248	Ammonium detoxifying activity is maintained after 72 hours of cold preservation of rat hepatocytes in University of Wisconsin (UW) solution. Cryo-Letters, 2002, 23, 245-54.	0.1	6
249	Nonalcoholic Fatty Liver Disease and Altered Neuropsychological Functions in Patients with Subcortical Vascular Dementia. Journal of Personalized Medicine, 2022, 12, 1106.	1.1	6
250	Competition of bile acids on the sulfobromophthalein uptake in basolateral rat liver plasma membrane vesicles. Biochemical Pharmacology, 1994, 48, 1301-1304.	2.0	5
251	Subzero nonfreezing storage of rat hepatocytes using UW solution and 1,4-butanediol. II- functional testing on rewarming and gene expression of urea cycle enzymes. Annals of Hepatology, 2009, 8, 129-133.	0.6	5
252	Multidrug resistance in hepatic cancer stem cells: the emerging role of miRNAs. Expert Review of Gastroenterology and Hepatology, 2015, 9, 723-725.	1.4	5

#	Article	IF	CITATIONS
253	A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects. Liver International, 2018, 38, 155-163.	1.9	5
254	The Novel N,Nâ€bisâ€2â€Hydroxyethylâ€2â€Aminoethanesulfonic Acid–Gluconate–Polyethylene Glycol–Hypothermic Machine Perfusion Solution Improves Static Cold Storage and Reduces Ischemia/Reperfusion Injury in Rat Liver Transplant. Liver Transplantation, 2019, 25, 1375-1386.	1.3	5
255	Life-Long Hyperbilirubinemia Exposure and Bilirubin Priming Prevent In Vitro Metabolic Damage. Frontiers in Pharmacology, 2021, 12, 646953.	1.6	5
256	Hepatitis C Virus-Related Central and Peripheral Nervous System Disorders. Brain Sciences, 2021, 11, 1569.	1.1	5
257	Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes. Annals of Hepatology, 2013, 13, 113-20.	0.6	5
258	Role and nature of plasma membrane carrier proteins in the hepatic transport of organic anions. Journal of Gastroenterology and Hepatology (Australia), 1989, 4, 195-205.	1.4	4
259	Efficient cold transfection of pea ferredoxin-NADP(H) oxidoreductase into rat hepatocytes. Journal of Gene Medicine, 2006, 8, 306-313.	1.4	4
260	Nonalcoholic Fatty Liver Is Not Associated with the Relationship between Insulin Secretion and Insulin Sensitivity in Obese Children: Matched Case–Control Study. Childhood Obesity, 2016, 12, 426-431.	0.8	4
261	A New Stage in Annals of Hepatology. Annals of Hepatology, 2018, 17, 339-340.	0.6	4
262	Differential capacity of CD90+ cells in autophagy activation following chemotherapy in hepatocellular carcinoma. Annals of Hepatology, 2020, 19, 645-652.	0.6	4
263	The mRNA Distribution of Cancer Stem Cell Marker CD90/Thy-1 Is Comparable in Hepatocellular Carcinoma of Eastern and Western Populations. Cells, 2020, 9, 2672.	1.8	4
264	Circulating microRNA Associated to Different Stages of Liver Steatosis in Prader–Willi Syndrome and Non-Syndromic Obesity. Journal of Clinical Medicine, 2020, 9, 1123.	1.0	4
265	The Relevance of SOCS1 Methylation and Epigenetic Therapy in Diverse Cell Populations of Hepatocellular Carcinoma. Diagnostics, 2021, 11, 1825.	1.3	4
266	Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Annals of Hepatology, 2008, 7, 157-60.	0.6	4
267	Role of hepatitis B virus in development of hepatocellular carcinoma: Focus on covalently closed circular DNA. World Journal of Hepatology, 2022, 14, 866-884.	0.8	4
268	Blue or green for yellow? Which light is more beneficial for jaundiced newborns?. Pediatric Research, 2019, 85, 747-747.	1.1	3
269	Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools—a narrative review. Annals of Translational Medicine, 2021, 9, 727-727.	0.7	3
270	Glycosylated 4â€methylumbelliferone as a targeted therapy for hepatocellular carcinoma. Liver International, 2022, 42, 444-457.	1.9	3

#	Article	IF	CITATIONS
271	ÂRapid identification system of frontal dysfunction in subclinical hepatic encephalopathy. Annals of Hepatology, 2016, 15, 559-67.	0.6	3
272	Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals. Cancers, 2022, 14, 2700.	1.7	3
273	Strategies in the study of hepatocellular carcinoma worldwide. Journal of Surgical Oncology, 1993, 53, 37-39.	0.8	2
274	Vagaries of impaired transporter function in PFIC 2 and 3. Hepatology, 2005, 42, 977-978.	3.6	2
275	Targeted multicomponent polysomes for high efficiency, simultaneous anti-sense and gene delivery. Soft Matter, 2011, 7, 9424.	1.2	2
276	Recent insights into hepatic cancer stem cells. Hepatology International, 2014, 8, 458-463.	1.9	2
277	Natural history of nonalcoholic steatohepatitis–associated hepatocellular carcinoma. Clinical Liver Disease, 2016, 8, 105-107.	1.0	2
278	Two drinks per day does not take your fatty liver away. Hepatology, 2018, 67, 2072-2073.	3.6	2
279	Why, What and Where: 3W in hepatology. Annals of Hepatology, 2019, 18, 409.	0.6	2
280	Cold storage of liver microorgans in ViaSpan and BG35 solutions: study of ammonia metabolism during normothermic reoxygenation. Annals of Hepatology, 2014, 13, 256-64.	0.6	2
281	Novel Function for Bilirubin as a Metabolic Signaling Molecule: Implications for Kidney Diseases. Kidney360, 0, , 10.34067/KID.0000062022.	0.9	2
282	Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2022, 23, 2813.	1.8	2
283	Estrogens keep alive the hepatocyte memory. Hepatology, 1988, 8, 693-695.	3.6	1
284	Detection of hepatitis B virus transcripts in patients with chronic liver disease. Journal of Hepatology, 1990, 10, 180-185.	1.8	1
285	Variation in UGT1A1 activity in Gilbert's syndrome. Journal of Hepatology, 2001, 34, 636-637.	1.8	1
286	Kernicterus, Bilirubin Induced Neurological Dysfunction and New Treatments for Unconjugated Hyperbilirubinemia. , 2012, , 621-628.		1
287	The impact of translational research on gastroenterology. Digestive and Liver Disease, 2014, 46, 293-294.	0.4	1
288	Neonatal hyperbilirubinemia. Italian Journal of Pediatrics, 2014, 40, A10.	1.0	1

#	Article	IF	CITATIONS
289	Modifications of IGF2 and EGFR plasma protein concentrations in NAFLD patients after bariatric surgery. International Journal of Obesity, 2021, 45, 374-382.	1.6	1
290	Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. , 2013, , 497-506.		1
291	Serum free fatty acids and bilirubin concentration during fasting in patients with Gilbert's syndrome and normal controls. Research in Clinic and Laboratory, 1987, 17, 61-6.	0.3	1
292	The Expression Level of ABCC6 Transporter in Colon Cancer Cells Correlates with the Activation of Different Intracellular Signaling Pathways. Pathophysiology, 2022, 29, 173-186.	1.0	1
293	Effect of Phototherapy on the Physiologic Cholestasis of the Neonate. Journal of Pediatric Gastroenterology and Nutrition, 1984, 3, 230-233.	0.9	Ο
294	Membrane potential and hepatic uptake: Another rule of the game. Hepatology, 1986, 6, 1049-1050.	3.6	0
295	Binding of tritiated bilirubin to albumin and plasma membrane vesicles: a reply. Biochemical Journal, 1997, 321, 261-261.	1.7	0
296	Response to Zucker: bilirubin and non-hepatic disease: a less jaundiced view. Trends in Molecular Medicine, 2005, 11, 314-315.	3.5	0
297	Editorial [Hot Topic: Bilirubin Induced Neurological Damage: From the Cell to the Newborn (Executive) Tj ETQq1 1	0.784314	l rgBT /Over
298	Ungebundenes (freies) Bilirubin: eine bessere Grundlage für die Bewertung des Icterus neonatorum / Unbound (free) bilirubin: improving the paradigm for evaluating neonatal jaundice. Laboratoriums Medizin, 2010, 34, 15-27.	0.1	0
299	Editorial: treatments for nonâ€alcoholic steatohepatitis ―still a long way to go. Alimentary Pharmacology and Therapeutics, 2017, 46, 700-701.	1.9	Ο
300	The Multifaceted Aspects of Modern Hepatology. Annals of Hepatology, 2021, , 100536.	0.6	0
301	Alcohol and Nutrition as Risk Factors for Chronic Liver Disease. , 2003, , 73-85.		0
302	The Hepatic Uptake of Organic Anions: An Overview. , 1987, , 31-40.		0
303	Kernicterus, Bilirubin-Induced Neurological Dysfunction, and New Treatments for Unconjugated Hyperbilirubinemia in Neonates. , 2018, , 1169-1184.		0
304	On the operational definition of fatty liver. Qeios, 0, , .	0.0	0